Diagnosis and Interim Treatment Outcomes from the First Cohort of Multidrug-Resistant Tuberculosis Patients in Tanzania

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Mpagama, Stellah G ^a,b   Heysell, Scott K ^c   Ndusilo, Nora D ^b   Kumburu, Happiness H ^b   Lekule, Isack A ^a   Kisonga, Riziki M ^a   Gratz, Jean ^b,c   Boeree, Martin J ^d   Houpt, Eric R ^c   Kibiki, Gibson S ^b  

^a Kibong'Oto National Tuberculosis Hospital   (Tanzania)

^b KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^c UNIVERSITY OF VIRGINIA   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; EFAVIRENZ; EMTRICITABINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LAMIVUDINE; LEVOFLOXACIN; MOXIFLOXACIN; NEVIRAPINE; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; BACTERIUM CULTURE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DRUG INDUCED HEADACHE; DRUG SENSITIVITY; EPIGASTRIC PAIN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYALGIA; NAUSEA AND VOMITING; PATIENT REFERRAL; PERIPHERAL NEUROPATHY; PSYCHOSIS; RASH; RETROSPECTIVE STUDY; SURVIVAL TIME; TANZANIA; TREATMENT OUTCOME;

ADULT; AMINOGLYCOSIDES; AMINOSALICYLIC ACID; ANTITUBERCULAR AGENTS; COMORBIDITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHIONAMIDE; FEMALE; FLUOROQUINOLONES; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; TANZANIA; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84877673828     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062034     Document Type: Article

References (26)

1. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. The Lancet 375: 1830-1843.
2. World Health Organization (2010) Global tuberculosis control. Geneva, World Health Organization.
3. World Health Organization (2011) Guidelines for the programmatic management of drug-resistant tuberculosis, Update. Geneva, World Health Organization.
4. Shenoi S, Heysell S, Moll A, Friedland G, (2009) Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect Dis 22: 11-17.
5. Chonde TM, Basra D, Mfinanga SG, Range N, Lwilla F, et al. (2010) National anti-tuberculosis drug resistance study in Tanzania. Int J Tuberc Lung Dis 14: 967-972.
6. Ministry of Health Tanzania. Health Sector Strategic Plan III (2009-2015).
7. Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, et al. (2011) Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PLoS ONE 6: e15841.
8. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, et al. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397-2405.
9. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, et al. (2009) Early Outcomes of MDR-TB Treatment in a High HIV-Prevalence Setting in Southern Africa. PLoS ONE 4: e7186.
10. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, et al. (2006) Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 144: 650-659.
11. Ministry of Health Tanzania (2010) Operational Guideline for the Management of Drug Resistant TB in Tanzania.
12. Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, et al. (2004) Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 8: 1382-1384.
13. Kibiki GS, Myers LC, Kalambo CF, Hoang SB, Stoler MH, et al. (2007) Bronchoalveolar neutrophils, interferon gamma-inducible protein 10 and interleukin-7 in AIDS-associated tuberculosis. Clin Exp Immunol 148: 254-259.
14. Brust JCM, Shah NS, Scott M, Chaiyachati K, Lygizos M, et al. (2012) Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis 16(8), 998-1004.
15. Loveday M, Wallengren K, Voce A, Margot B, Reddy T, et al. (2012) Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. The International J Tuberc and Lung Dis 16(2), 209-215.
16. Satti H, McLaughlin MM, Hedt-Gauthier B, Atwood SS, Omotayo DB, et al. (2012) Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLoS ONE 7: e46943.
17. Dhingra VK, Rajpal S, Mittal A, Hanif M, (2008) Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic. Indian J Tuberc 55: 15-21.
18. Kruuner A, Jureen P, Levina K, Ghebremichael S, Hoffner S, (2003) Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 2971-2973.
19. Heysell SK, Mtabho C, Mpagama S, Mwaigwisya S, Pholwat S, et al. (2011) Plasma drug activity assay for treatment optimization in tuberculosis patients. Antimicrob Agents Chemother 55: 5819-5825.
20. Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, et al. (2006) Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 28: 980-985.
21. Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, et al. (2001) Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 5: 648-655.
22. Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, et al. (2004) Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 8: 1382-1384.
23. Torun T, Gungor G, Ozmen I, Bolukbasi Y, Maden E, et al. (2005) Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9: 1373-1377.
24. Francis J Curry National Tuberculosis Center and California Department of Health (2008) Drug Resistant Tuberculosis A Survival Guide for Clinicians. 86-87.
25. Thomas TA, Shenoi SV, Heysell SK, Eksteen FJ, Sunkari VB, et al. (2010) Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa. Int J Tuberc Lung Dis 14: 1244-1251.
26. Caminero JA, Sotgiu G, Zumla A, Migliori GB, (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. The Lancet Infectious Diseases 10: 621-629.